Julie Allickson, Ph.D., has been named the Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Medicine and the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Medicine. Dr. Allickson joins Mayo Clinic from Wake Forest Institute for Regenerative Medicine at Wake Forest School of Medicine, where she is the chief manufacturing development center officer. She will begin her new role on Aug. 9.
In her new role, Dr. Allickson will lead the next phase of development of the Center for Regenerative Medicine as it delivers on innovations that Cure, Connect and Transform patient care in alignment with Mayo Clinic's 2030 vision. She will direct the enterprise-wide biomanufacturing strategy that aspires to introduce new regenerative therapeutics into the practice and establish Mayo Clinic as a category of one in regenerative medicine for rare and complex conditions. Dr. Allickson will provide strategic leadership for all center activities and operations across Mayo Clinic.
"I'm very excited for the opportunity to lead a talented team at Mayo Clinic focused on executing a new biomanufacturing strategy to bring new cures to the practice and deliver next generation therapeutics that further enhance Mayo Clinic's reputation as a global leader in regenerative medicine," says Dr. Allickson.
Team science is the hallmark of success at Mayo Clinic. In keeping with that tradition, Dr. Allickson will promote collaboration with Mayo Clinic's Department of Laboratory Medicine and Pathology and the Mayo Clinic Cancer Center, focusing on developing regenerative biotherapies. She will design, develop and facilitate alliances with academia, industry and governmental agencies to bring regenerative medicine to patients worldwide, including those in underserved communities.
With more than 25 years of experience in clinical translation of cellular therapies and regenerative medicine products, Dr. Allickson has expertise in business management, regulatory affairs, strategic planning, project management and team-building. She has served as an executive officer of a publicly traded company that builds services for cellular banking, including licensure of technology with several international affiliates.
"Mayo Clinic is making a significant investment in biomanufacturing to create a supply chain of innovative regenerative therapeutics for decades to come. This is a huge opportunity to address the unmet needs of patients, particularly those that need top of the pyramid care and to engage with industry to commercialize new discoveries made at Mayo Clinic," says Dr. Allickson.
Mayo Clinic established the Center for Regenerative Medicine in 2011 as an investment in the future of health care. Regenerative medicine is changing the focus of health care from fighting disease to building health. The Center for Regenerative Medicine has been at the forefront of this movement, advancing regenerative sciences research, education and practice that position Mayo Clinic as the premier destination for regenerative care. The Center for Regenerative Medicine has over 200 clinical trials and projects underway and has filed more than 150 regenerative patents. The center performs over 100,000 regenerative procedures annually.
Dr. Allickson succeeds Andre Terzic, M.D., Ph.D., who has provided outstanding leadership and made extraordinary contributions to the Center for Regeneration Medicine for nearly 10 years. Dr. Terzic was instrumental in advancing the field of regenerative medicine at Mayo Clinic through scientific discovery, academic advancement and clinical innovation. Under Dr. Terzic's leadership, the center has made significant advances in regenerative care and its aim to shift the health care paradigm from treating disease to restoring and improving health.